While I am happy to see leaks about exciting potential in the pipeline, the primary hurdle to approval remains financing. The commercial success of Afrezza will fund some of the innovative product development the company has in mothballs. Technosphere has the potential to generate revenue for literally dozens of drugs that could benefit from a new delivery platform.

I used to get very excited about things that could turn into revenue 5-10 years down the road. Lately I spend my days wondering why there has been no discernable movement to solve the financing crisis the company faces. Nobody at MannKind seems terribly concerned about resolving the money issue. Does that translate into management has an effective plan to resolve the issue or does that mean that all the plans have been submarined and it is time to massively dilute again? If it is the former it is time to add more.